Pharma Marketletter articles from September 2004

Pharma Marketletter archives from September 2004

Edis buys 87.5% stake in Serdix.(Brief Article)
September 6, 2004... Hungarian drugmaker Edis has purchased an 87.5% stake in the Russian drugs producer Serdix for $3.5 million, according to the Interfax news agency. The purchase price will be paid in the form of a capital increase in Serdix. In line with...

GSK gets off lightly with $2.5m settlement in Spitzer case.(GlaxoSmithKline 's case with Attorney General Eliot Spitzer has been settled)(Brief Article)
September 6, 2004... UK drug major GlaxoSmithKline saw its shares rise 1.2% to L11.45 in early trading on August 27, reflecting investors' relief on the previous day's news that the firm had settled its case with the New York Attorney General's Office over its...

Ranbaxy to expand to Canada and Portugal.(Ranbaxy Laboratories Ltd.)(Brief Article)
September 6, 2004... New Delhi, India-based Ranbaxy Laboratories is setting up two new overseas subsidiaries in Portugal and Canada, in order to establish its presence in potential markets across the globe, says the firm's chief executive, Brian Tempest. India...

US judge OKs changes for fen-phen claims.(Brief Article)
September 6, 2004... A US District Judge has granted preliminary approval of the proposed Seventh Amendment to the national diet-drug settlement regarding US drugmaker Wyeth's Pondamin (fenfluramine), and has directed that notice of the Amendment be provided to...

DeCode's accountants resign.(deCODE genetics Inc., PricewaterhouseCoopers L.L.P. (New York, New York))(Brief Article)
September 6, 2004... USA-based firm DeCode Genetics has reported the resignation of its accountants, PriceWaterhouseCoopers. The firm has said that there were no disputes with its accountants, which have served DeCode since 1996.

Myeloma Institute wins $18M grant.(Myeloma Institute for Research and Therapy)(Brief Article)
September 6, 2004... The US Myeloma Institute for Research and Therapy, a part of the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences, has received a US National Cancer Institute grant worth nearly $18 million, one of the largest...

$1M deposit for Generex from Sejong.(Generex Biotechnology Corp., Sejong Capital )(Brief Article)
September 6, 2004... Canada's Generex Biotechnology, which focusses on the area of buccal drug-delivery, has announced that Sejong Capital (now known as Charmed Capital), its joint venture partner for the commercialization of Oralin (oral insulin spray formulation)...

US firm in Japanese ECG studies accords.(eResearchTechnology Inc.)(Brief Article)
September 6, 2004... eResearchTechnology, a US provider of centralized electrocardiographic collection and interpretation services, has been awarded two studies valued at around $1.1 million from the Japanese operation of a top-20 global pharmaceutical company for...

AstraZeneca's Iressa "Oncology Compound of Year".(Brief Article)
September 6, 2004... AstraZeneca says that its novel anticancer agent Iressa (gefitinib) was named the Oncology Compound of the Year, together with the USA's Millennium Pharmaceutical's bortezomib, at the Third Annual Pharmaceutical Achievement Awards held recently...

US HHS issues national pandemic flu preparedness plan.(Health and Human Services )(Brief Article)
September 6, 2004... The US Department of Health and Human Services has unveiled its draft Pandemic Influenza Response and Preparedness Plan, outlining a coordinated national strategy to prepare for and respond to an influenza pandemic. It can be found on-line at...

Cost-lowering by US Medicare enrollees who exceed Rx caps: study.
September 6, 2004... US Medicare + Choice beneficiaries who exceed the annual dollar limits or caps on their prescription drug coverage and then face coverage gaps until year-end often decrease the use of essential medications and experience difficulty paying for...

Patients need Rx choice for best treatment: study.
September 6, 2004... A new study commissioned by the Pharmaceutical Research and Manufacturers of America shows the importance of ensuring that patients and physicians have access to a range of medicines within therapeutic classes for diseases such as high blood...

Bush plan works to make health more affordable, accessible: Thompson.(George W. Bush, Tommy Thompson)
September 6, 2004... UK President George W Bush's efforts to reduce costs and improve access to health care, while building on the strengths of the private health care system, are the best ways to provide affordable coverage for more Americans, according to Health...

Massive growth potential of ChinaOs hepatitis market: study.
September 6, 2004... Around 160 million people in China are estimated to suffer from chronic hepatitis B and C, offering considerable economic potential for both foreign and domestic drugmakers, says a new study from Datamonitor. However, it adds,...

How to satisfy the FDA and understand cGMP: UK course.(Brief Article)
September 6, 2004... A new training course to steer drugmakers through the tricky process of US Food and Drug Administration approval has been launched by RSSL Pharma Training of the UK. A main concern regarding US current Good Manufacturing Practice is the...

India to bring more drugs under price watch.(National Pharmaceutical Pricing Authority)(Brief Article)
September 6, 2004... India's National Pharmaceutical Pricing Authority is to monitor the prices of medicines with annual turnover of 10-40 million rupees ($216,000-$863,850), the Federal Minister for Chemicals and Fertilizers, Ram Vilas Paswan, has announced. ...

US pharmacies sue big pharma over price OconspiracyO.(Brief Article)
September 6, 2004... A law suit filed in the US state of California by 19 independent pharmacies has accused the world's 15 leading pharmaceutical firms of constructing an "artificial trade barrier and wall around the USA for the purpose of preventing the...

NicOx and Pfizer enter collaboration.(Brief Article)
September 6, 2004... France-based NicOx says it has signed an agreement with US drug major Pfizer regarding its proprietary nitric oxide-donating compounds. Under the terms of the accord, the French firm has granted Pfizer an option to acquire an exclusive...

Aphton's Insegia filed in Canada.(Brief Article)
September 6, 2004... The USA's Aphton Corp has filed for approval of its anti-gastrin immunogen Insegia (G17DT) with Health Canada. The product is indicated as a monotherapy for the treatment of advanced pancreatic cancer in patients who are either unable to...

Forest pursues new use for Lexapro.(Brief Article)
September 6, 2004... Forest Laboratories has submitted a complete response to deficiencies raised by the US Food and Drug Administration's Division of Neuropharmacological Drug Products in its review of the supplemental New Drug Application for Lexapro...

Lutein and zeaxanthin crucial for good vision.(Brief Article)
September 6, 2004... A new study published in the September issue of Investigative Ophthalmology and Visual Science has shown that the two carotenoids zeaxanthin and lutein play a vital role in maintaining the distribution of Retinal Pigment Epithelium cells; the...

Vit B12 may prevent birth defects.(Vitamin B12)(Brief Article)
September 6, 2004... Mothers with low levels of vitamin B12 in their blood are at increased risk of having a child with spina bifida, a birth defect in which the spinal cord does not form properly, according to Dutch scientists. Women are currently recommended...

Butterbur no benefit for hay fever sufferers.(Brief Article)
September 6, 2004... A study reported in July's issue of the Annals of Allergy Asthma Immunology suggests that the herbal remedy butterbur appears to have no impact on hay fever symptoms. Earlier this year, the researchers from the University of Dundee,...

Ginseng reduces warfarin efficacy.(Brief Article)
September 6, 2004... Findings published in the Annals of Internal Medicine suggest that the widely-used herbal supplement ginseng reduces the effects of the anticoagulant warfarin. According to the lead researcher Chun-Su Yuan from the University of Chicago,...

Idenix swings to profit in 2nd-qtr 2004.(financial reports)(Brief Article)
September 6, 2004... Idenix Pharmaceuticals swung to profit for the second quarter of 2004, although this was solely due to a $25-million milestone payment from Swiss drugmaker Novartis AG regarding the completion of a Phase I trial of NM 283, the firm's lead...

Progen sees sales and net loss down for fiscal 2004.(financial reports)(Brief Article)
September 6, 2004... Progen Industries of Australia, which is focused on the development of anti-cancer therapies, has reported a solid financial performance for fiscal 2004 ended June 30, reflecting concerted capital and resource management and a cash/cash...

Tokyo pharma stocks - 2 weeks to August 30.
September 6, 2004... Tokyo saw a rally in the two weeks ended August 30 on buying-back of major high-technology shares as well as of low-priced stocks on weakness. The Nikkei 225 rose 4.6%, to close above the psychologically-important 11,000 level, while the Topix...

Mylan withdraws law suit against FDA.(United States. Food and Drug Administration)(Brief Article)
September 6, 2004... Mylan Pharmaceuticals has filed a notice of voluntary dismissal without prejudice in the US District Court for the Northern District of West Virginia in its law suit against the Food and Drug Administration on the issue of authorized generics...

Hybridon closes $5.1M placing.(Brief Article)
September 6, 2004... US firm Hybridon has raised $5.1 million in gross proceeds from a private equity placement to institutional and overseas investors. In the financing, the company sold approximately 8.8 million shares at a price of $0.58 each and warrants to...

Cryptome gets grant for antithrombotic development.(Cryptome Pharmaceuticals)(Brief Article)
September 6, 2004... Australian protein-focused drug discovery company Cryptome Pharmaceuticals says that development work on its lead drug candidate, the anti-coagulant CR001, will be boosted by a A$1.95 million ($1.4 million) AusIndustry R&D START grant. The...

Pharma firms suffering e-mail overload.
September 6, 2004... Health care and pharmaceutical firms' managers store nearly 50% more e-mails than their peers in other industries, putting pressure on storage space, information sharing and worker productivity, a survey has found. The study, commissioned by...

USP told: formularies need flexibility.(United States Pharmacopoeia )
September 6, 2004... Managed care pharmacy organizations must have sufficient flexibility to create formularies under the US Medicare prescription drug discount benefit that will successfully meet patient needs and, at the same time, allow prescription drug...

Schwarzenegger veto threat to Rx import bills.(California Governor, Arnold Schwarzenegger)
September 6, 2004... The Legislature of the US state of California has passed two bills which would enable the creation of government-sponsored web sites allowing consumers in the state to buy prescription drugs from Canada. However, and despite the fact that...

US state may adopt Australian Rx price plan.(prescription drug )(Brief Article)
September 6, 2004... The US state of West Virginia is examining a proposal to adopt the prescription drug reference price schedule used by Australia to negotiate with drugmakers. The proposal, made by the West Virginia Pharmaceutical Cost Management Council,...

Warning over UK NICE Tamiflu guidance.(United Kingdom. National Institute for Clinical Excellence)
September 6, 2004... Complying with the UK National Institute for Clinical Excellence guideline on the use of Gilead Sciences/Roche's Tamiflu (oseltamivir) to prevent flu may be impractical and costly, says new research published by the British Medical Journal. ...

German pharmacies hit by Internet drug trade.(Brief Article)
September 6, 2004... German pharmacies' sales have fallen in the six months since price restrictions on non-prescription drugs were removed and, says a Sempora Consulting report, "aggressive price offers" and cooperation with health funds have expanded the client...

Irish Rx trade, price data.(pharmaceutical products )(Brief Article)
September 6, 2004... Ireland exported medical and pharmaceutical products worth 5.95 billion euros ($7.20 billion) in the first five months of 2004, against 5.46 billion euros in the same period of 2003, reports the Irish Central Statistical Office. Imports of...

Letter from the Editor.
September 6, 2004... France may have joined the "Pharma Big League" via the merger of Sanofi-Synthelabo and Aventis to create Sanofi-Aventis, now the world's third-largest drugmaker, but it is left with just one pharmaceutical company of any international...

Bayer sees shares dip on mixed 2nd-qtr.(finance)
September 6, 2004... German drugmaker Bayer turned in a mixed set of results for the second quarter ended June 30, as earnings before interest and tax, excluding special items, beat forecasts, but profit undershot its target. An unexpectedly good result for...

Sanofi posts strong first-half results.(Sanofi-Synthelabo S.A.)
September 6, 2004... France-based Sanofi-Synthelabo, which has now merged with Aventis, has posted a strong set of results for the first half of 2004, slightly over expectations and marking the last financial period as an independent company. Sanofi generated...

Sanofi-Aventis' Acomplia aids weight loss and reduces CVD risk factors.(cardiovascular diseases)
September 6, 2004... First-year findings from a two-year Phase III trial of Sanofi-Aventis' Acomplia (rimonabant) reveal that the agent reduces body weight and waist circumference and improves lipid and glycemic profiles in overweight or obese patients. These...

Novartis' Certican delayed in USA.(Brief Article)
September 6, 2004... Swiss drug major Novartis says it has received an approvable letter from the US Food and Drug Administration for Certican (everolimus) in combination with Neoral (ciclosporin for microemulsion) for the prevention of rejection episodes following...

Medimmune halts Vitaxin trials.(Brief Article)
September 6, 2004... MedImmune says it has decided to discontinue Phase II trials of Vitaxin in patients with rheumatoid arthritis and psoriasis. The decision was based on preliminary findings which indicated a lack of clinical benefit with the drug; there were no...

TACI-Ig begins clinical study in RA patients.(ZymoGenetics/Serono, rheumatoid arthritis)(Brief Article)
September 6, 2004... ZymoGenetics/Serono's TACI-Ig has begun a Phase Ib clinical trial in patients with rheumatoid arthritis. The study will evaluate the safety and pharmacokinetic profile of the agent, as well as its preliminary efficacy. TACI-Ig is a soluble...

Othera raises $13M in a Series B financing.(Othera Pharmaceuticals)(Brief Article)
September 6, 2004... Privately-held US firm Othera Pharmaceuticals, which is focused on the development of products to treat or prevent the three leading causes of blindness, has raised $13 million in a Series B round of financing. The firm intends to use the...

BioAlliance closes 12 million-euro Series C financing.(Brief Article)
September 6, 2004... BioAlliance Pharma SA, a privately-held biopharmaceutical company specializing in drug resistance, has raised an extra 2.0 million euros ($2.4 million) to close its third round of financing at 12 million euros. The additional investment...

Xenova gets ahead of itself on sale of facility.(to QSV Logistics)(Brief Article)
September 6, 2004... UK-based Xenova yesterday announced, prematurely, the completion of the sale of its manufacturing plant in Edmonton, Canada, with a statement to the London, UK, Stock Exchange saying that it had sold the facility to QSV Logistics, also of the...

UCB reorganizes R&D operations.(UCB Pharma N.V./S.A.)(Brief Article)
September 6, 2004... Belgium-based drugmaker UCB Pharma has restructured its R&D operations following its recent acquisition of the UK's Celltech (Marketletters passim), with the aim of creating research centers in Braine-l'Alleud, Belgium, and in Slough and...

Disappointing new data for Merck & Co's Zocor in patients with ACS.(Acute Coronary Syndromes )
September 6, 2004... Merck & Co's cholesterol therapy Zocor (simvastatin) has suffered a setback after the publication of disappointing findings in the Journal of the American Medical Association from a trial evaluating the safety and efficacy of a high dose of the...

Forest's neramexane fails in Ph III trial.(Forest Laboratories)(Brief Article)
September 6, 2004... USA-based Forest Laboratories says that a Phase III study of its Alzheimer's disease therapy, neramexane, failed to meet its primary objectives. The six-month, double-blind, parallel-group trial was designed to examine the safety and...

Emselex shows good safety profile.(Novartis)(Brief Article)
September 6, 2004... New data shows that Novartis' Emselex (Enablex; darifenacin hydrobromide) has better tolerability and equal efficacy to oxybutynin in the treatment of overactive bladder. The findings showed that two weeks' therapy with both Emselex 15mg...

MGI goes on $82M spending spree.(MGI Pharma acquired Zycos for $50 million and Aesgen for $32 million)(Brief Article)
September 6, 2004... The USA's MGI Pharma has shelled out $82 million in cash on two simultaneously-announced acquisitions: Zycos for $50 million and Aesgen for $32 million, marking a significant step towards building a leading oncology portfolio. The...

Akzo marries Diosynth and Organon.(Akzo Nobel )(Brief Article)
September 6, 2004... Dutch drugmaker Akzo Nobel has integrated its two pharmaceutical units - Diosynth and Organon - to create a single entity, to be called Organon, with the aim of strengthening the group's pharmaceutical business. To support this move, 60...

Pharming reduces net loss for first-half 2004.(Pharming Group )(Brief Article)
September 6, 2004... Netherlands-based Pharming Group has posted a decline in net loss for the first six months of 2004, down 15% at 5.1 million euros ($6.1 million) from the same period of last year. Total revenues of 300,000 euros were level with those...

South African High Court rejects call to throw out drug pricing regs.
September 6, 2004... The High Court in Cape Town, South Africa, has rejected an application to overturn the country's controversial new drug pricing regulations and, as a result, the Department of Health said that they will be implemented immediately. However,...

GSK: voluntary license for ARVs in South Africa.(GlaxoSmithKline)(Brief Article)
September 6, 2004... GlaxoSmithKline has granted a voluntary license to Feza Pharmaceuticals, a joint venture between Creative Outsourcing Solutions International and African Healthcare Solutions, for the manufacture, import and sale of antiretrovirals containing...

S Africa Rx prices in July.(Brief Article)
September 6, 2004... July's producer price of pharmaceuticals in South Africa was 4.5% lower than June and 3.7% down on July 2003, says Statistics South Africa. The producer price of South African drugs made for export was 8% lower month-on-month but up 7.8%...

US FDA head welcomes pharma trial data moves.(United States. Food and Drug Administration)
September 6, 2004... The posting of key clinical trial information on-line raises the related question of what is or is not appropriate to be posted, US Food and Drug Administration Acting Commissioner Lester Crawford has said. This is obviously difficult when...

Bush will empower those who cure you, GOP told.(Grand Old Party)
September 6, 2004... US Democratic Presidential nominee John Kerry remains the "personal injury lawyers' best friend," but President George W Bush will put the interests of patients, doctors and nurses first, according to US Senate Majority leader Bill Frist,...

US pharma election spend: "$870,000+ for Bush".(Brief Article)
September 6, 2004... The pharmaceutical industry has donated at least $870,000 to US President George W Bush during this election cycle, with Democratic nominee John Kerry receiving around $350,000, according to an Associated Press report. Drug industry...

A$3.8M share placement by AustCancer.(Australian Cancer Technology Ltd)(Brief Article)
September 6, 2004... Biotechnology company Australian Cancer Technology has announced the placement of 9,485,000 fully-paid ordinary shares at A$0.40 per share, to raise just under A$3.8 million ($2.6 million) before costs and 1,654,000 three-year options,...

TKT will defend itself in Serono patent litigation.(Brief Article)
September 6, 2004... Following notification that Serono of Switzerland's US subsidiary Applied Research Systems had filed an amended complaint against Transkaryotic Therapies in the US District Court of Massachusetts, TKT has said it will defend itself...

New venture fund to invest in NJ biotechs.(Brief Article)
September 6, 2004... In the USA, the New Jersey Economic Development Authority has entered into a 10-year limited partnership agreement with Quaker BioVentures to create and manage the $10 million Garden State Life Sciences Venture Fund that will make investments...

Chiron acquires Prion Solutions.
September 6, 2004... Leading US biotechnology firm Chiron Corp says that it has acquired Prion Solutions, a privately-held company based in La Jolla, California, focused on research into variant Creutzfeldt-Jakob disease and other prion-related conditions....

Sanofi-Aventis' Acomplia will have huge impact on obesity market.(Brief Article)
September 6, 2004... Decision Resources, a research and advisory firms focusing on pharmaceutical and health care issues, finds that Sanofi-Aventis's Acomplia (rimonabant; see also page 18), a novel cannabinoid CB1 receptor antagonist, will have a huge impact on...

Impax comments on Rilutek generic ruling.
September 6, 2004... Impax Laboratories of the USA says that the District Court of Wilmington, Delaware, has ruled that Aventis Pharmaceutical's patent 5,527,814 related to the use of Rilutek (riluzole) for the treatment of amyotrophic lateral sclerosis, also known...

Novartis honors diabetes researchers.(Brief Article)
September 6, 2004... Four physician-scientists have been recognized by Novartis for significant and innovative research, clinical practice advances and educational efforts in diabetes. The recipients of the sixth annual Novartis Award in Diabetes will be honored at...

Apointments and dismissals at Sanofi-Aventis.(Brief Article)
September 6, 2004... Juergen Dormann is to become a vice-president on the Sanofi-Aventis group board, according to a decision taken by the new board. Mr Dormann has been president and president of the supervisory board of the Franco-German pharmaceutical group...

Richter Gedeon in Indian JV with Themis.(Themis Medicare)(Richter-Themis Medicare (India))(Brief Article)
September 6, 2004... Hungary's Richter Gedeon and India's Themis Medicare have agreed to set up a joint-venture company in India for the production of active pharmaceutical ingredients. The new firm, to be called Richter-Themis Medicare (India), will be 51%-owned...

New president of TAP Pharma named.(TAP Pharmaceutical Products )(Brief Article)
September 6, 2004... TAP Pharmaceutical Products, a joint venture of Abbott Laboratories and Takeda Pharmaceutical, has appointed Alan MacKenzie as president, succeeding Thomas Watkins, effective September 1, upon the expiration of the latter's term. Mr MacKenzie...

Novo Nordisk completes $6M investment in Transition Therapeutics.(Brief Article)
September 6, 2004... Denmark's Novo Nordisk has completed its investment of some $6 million in Canadian firm Transition Therapeutics, with the latter issuing 5 million shares at $1.20 each to the former. Proceeds of the financing will be used by Transition for...

Italy's Acraf takes 10% stake in Elder of India.(Elder Pharmaceuticals)(Brief Article)
September 6, 2004... Italian drugmaker Acraf SpA has acquired a 10% stake in India's Elder Pharmaceuticals and has said it will invest over 250 million rupees ($5.4 million) as part of the acquisition. HSBC Financial Services, based in Mauritius, has already bought...

Vioxx study indicates heart risks.(Brief Article)
September 6, 2004... Results from a US Food and Drug Administration-financed study of Merck & Co's Vioxx (rofecoxib), presented at an epidemiologists conference in Bordeaux, France, on August 25, indicate that patients taking the antiarthritic agent have a 50%...

GPC initiates Phase I/II trial of satraplatin in combination with radiation therapy.(GPC Biotech )(Brief Article)
September 6, 2004... German drugmaker GPC Biotech says that its Phase I/II clinical trial, designed to evaluate the combination of its lead drug satraplatin and simultaneous radiation therapy in patients with locally-advanced non-small cell lung cancer, has...

Takeda plans to file for US approval of TAK-375.(Brief Article)
September 6, 2004... Japan's Takeda plans to file an application for the US approval of TAK-375 (ramelteon), a treatment for primary insomnia currently in Phase III clinical trials in the USA. The firm has also upgraded three lifestyle improving compounds to the...

FDA and Pfizer warn doctors of Geodon link to hyperglycemia and diabetes.(Brief Article)
September 6, 2004... Pharmaceutical giant Pfizer and the US Food and Drug Administration have warned doctors that the firm's antipsychotic drug Geodon (ziprasidone) has been linked to significantly elevated blood-sugar levels and diabetes. Pfizer's warning letter,...

New River's NRP104 gets fast-track designation for cocaine dependence from FDA.(New River Pharmaceuticals)(Food and Drug Administration)(Brief Article)
September 6, 2004... New River Pharmaceuticals' NRP104 has been granted fast- track status for the treatment of cocaine dependence by the US Food and Drug Administration. Commenting on the product's potential, Rob Oberlander, director of drug abuse science and...

Atrix and Fujisawa Healthcare submit NDA for Aczone for acne.(New Drug Application)(Brief Article)
September 6, 2004... The USA's Atrix Laboratories and co-development partner Fujisawa Healthcare have submitted a New Drug Application to the US Food and Drug Administration for Aczone (dapsone, topical) Gel 5%, formerly called Atrisone, for the treatment of acne...

AVI Biopharma to initiate clinical trial of AVI-4020 for West Nile Virus neuroinvasive disease.(Brief Article)
September 6, 2004... USA-based AVI Biopharma plans to initiate a double-blind, multicenter clinical trial with its Neugene antisense drug candidate, AVI-4020, for the treatment of patients with acute West Nile virus disease who have WNV neuroinvasive disease....

Jeffrey Aracara named VP, commercial devel, at InKine.(InKine Pharmaceutical Company Inc.)(Brief Article)
September 6, 2004... US specialty firm InKine Pharmaceuticals has promoted Jeffrey Arcara to the post of vice president of commercial development.

MediGene names Ulrich Delvos to exec board for R&D.(Brief Article)
September 6, 2004... German biotechnology company MediGene AG has appointed former Aventis Behring manager Ulrich Delvos as executive board member for R&D.

BioXell names Anke Domdey preclinical development director.(Brief Article)
September 6, 2004... Italian biopharmaceutical firm BioXell SpA has named Anke Domdey, ex-Boehringer Ingelheim, as preclinical development director.

Sanitas seeking to take over Kalcek's injectables production.(Grindeks)(Brief Article)
September 6, 2004... Lithuanian drugmaker Sanitas is holding talks with Latvian firm Grindeks on taking over the production of injectable medicines from its subsidiary Kalceks, according to the LETA news agency. The negotiations concern strategic cooperation and...

Sanofi-Aventis hives off antibiotics R&D.(Brief Article)
September 6, 2004... Sanofi-Aventis has hived off its antibiotics R&D operations into a new firm, Novexel, now being sold to an Atlas-led group of investors.